Gevork Minaskanian

Last updated • 1 min readFrom Wikipedia, The Free Encyclopedia

Gevork Minaskanian is an American research professor in the Department of Chemistry at Virginia Commonwealth University [1] and Co-founder/Vice President of Synthetic Chemistry [2] at Aderis Pharmaceuticals who was a contributor to the development of rotigotine and Neupro (a transdermal patch that delivers rotigotine). Rotigotine is a drug developed to mimic the actions of dopamine in the brain to help cope with restless legs syndrome and the abnormal movements(dyskinesia) found in Parkinson's disease patients. This drug is an alternative to oral medications for the treatment of Parkinson's disease, considered by the VCU Department of Chemistry as "an unprecedented medication for the benefit of millions of Parkinson's patient worldwide." [3] Minaskanian’s main contribution to Neupro was improving the efficiency of manufacturing rotigotine, thereby making the process commercially viable and enabling patients to afford this important medication. Dr. Minaskanian is the inventor and author of over 50 patents and publications in various fields of organic and medicinal chemistry. Some of his US patents include patents 5,470,848; [4] 4,801,586; [5] 5,234,959; [6] 5,118,676; [7] and other related research done on rotigotine and Neupro US patent 7,309,497 [8] found in the United States Patent and Trademark Office linked to the penetration enhancers for transdermal delivery of systemic agents.

Related Research Articles

<span class="mw-page-title-main">Fentanyl</span> Opioid medication

Fentanyl is a highly potent synthetic piperidine opioid primarily used as an analgesic. It is 30 to 50 times more potent than heroin and 100 times more potent than morphine; its primary clinical utility is in pain management for cancer patients and those recovering from painful surgeries. Fentanyl is also used as a sedative. Depending on the method of delivery, fentanyl can be very fast acting and ingesting a relatively small quantity can cause overdose. Fentanyl works by activating μ-opioid receptors. Fentanyl is sold under the brand names Actiq, Duragesic, and Sublimaze, among others.

<span class="mw-page-title-main">Ibuprofen</span> Medication treating pain, fever, and inflammation

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be taken orally or intravenously. It typically begins working within an hour.

<span class="mw-page-title-main">Medication</span> Substance used to diagnose, cure, treat, or prevent disease

A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.

<span class="mw-page-title-main">Pharmacy</span> Clinical health science

Pharmacy is the science and practice of discovering, producing, preparing, dispensing, reviewing and monitoring medications, aiming to ensure the safe, effective, and affordable use of medicines. It is a miscellaneous science as it links health sciences with pharmaceutical sciences and natural sciences. The professional practice is becoming more clinically oriented as most of the drugs are now manufactured by pharmaceutical industries. Based on the setting, pharmacy practice is either classified as community or institutional pharmacy. Providing direct patient care in the community of institutional pharmacies is considered clinical pharmacy.

<span class="mw-page-title-main">Pharmaceutical industry</span> Industry involved with discovery, development, production and marketing of drugs

The pharmaceutical industry is an industry involved in medicine that discovers, develops, produces, and markets pharmaceutical goods for use as drugs which are then administered to patients. These medications are created and put to market for the curing or preventing of disease, as well as alleviating symptoms of illness or injury.

<span class="mw-page-title-main">Topical medication</span> Medication applied to body surfaces

A topical medication is a medication that is applied to a particular place on or in the body. Most often topical medication means application to body surfaces such as the skin or mucous membranes to treat ailments via a large range of classes including creams, foams, gels, lotions, and ointments. Many topical medications are epicutaneous, meaning that they are applied directly to the skin. Topical medications may also be inhalational, such as asthma medications, or applied to the surface of tissues other than the skin, such as eye drops applied to the conjunctiva, or ear drops placed in the ear, or medications applied to the surface of a tooth. The word topical derives from Greek τοπικόςtopikos, "of a place".

<span class="mw-page-title-main">Selegiline</span> Monoamine oxidase inhibitor

Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Zelapar, and Emsam among others, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. It has also been studied and used off-label for a variety of other indications, but has not been formally approved for any other use. The medication, in the form licensed for depression, has modest effectiveness for this condition that is similar to that of other antidepressants. Selegiline is provided as a swallowed tablet or capsule or an orally disintegrating tablet (ODT) for Parkinson's disease and as a patch applied to skin for depression.

<span class="mw-page-title-main">Robert S. Langer</span> American scientist

Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the nine Institute Professors at the Massachusetts Institute of Technology.

<span class="mw-page-title-main">UCB (company)</span> Biopharmaceutical company

UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders, inflammatory disorders, and oncology.

<span class="mw-page-title-main">Dopamine agonist</span> Compound that activates dopamine receptors

A dopamine agonist is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors. Dopamine agonists are primarily used in the treatment of the motor symptoms of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome. They are also used off-label in the treatment of clinical depression. Impulse control disorders are associated with the use of dopamine agonists for whatever condition.

<span class="mw-page-title-main">Oxybutynin</span> Medication for overactive bladder

Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder. It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time. It works similar to tolterodine, darifenacin, and solifenacin, although it is usually preferred over these medications. It is sometimes used off-label for treatment of hyperhidrosis, or excessive sweating. It has also been used off-label to treat bedwetting in children, but this use has declined, as it is most likely ineffective in this role. It is taken by mouth or applied to the skin.

<span class="mw-page-title-main">Rotigotine</span> Dopamine agonist medication

Rotigotine, sold under the brand name Neupro among others, is a dopamine agonist of the non-ergoline class of medications indicated for the treatment of Parkinson's disease and restless legs syndrome. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

<span class="mw-page-title-main">Drug delivery</span> Methods for delivering drugs to target sites

Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to optimize efficacy and safety, and to improve patient convenience and compliance. Drug delivery is aimed at altering a drug's pharmacokinetics and specificity by formulating it with different excipients, drug carriers, and medical devices. There is additional emphasis on increasing the bioavailability and duration of action of a drug to improve therapeutic outcomes. Some research has also been focused on improving safety for the person administering the medication. For example, several types of microneedle patches have been developed for administering vaccines and other medications to reduce the risk of needlestick injury.

<span class="mw-page-title-main">Bornaprine</span> Chemical compound

Bornaprine is a synthetic anticholinergic medication that is primarily used to treat Parkinson's disease. Additionally, bornaprine has been used to treat other disorders, including hyperhidrosis.

Drug discovery and development requires the integration of multiple scientific and technological disciplines. These include chemistry, biology, pharmacology, pharmaceutical technology and extensive use of information technology. The latter is increasingly recognised as Pharmacoinformatics. Pharmacoinformatics relates to the broader field of bioinformatics.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

<span class="mw-page-title-main">Cynapsus Therapeutics</span>

Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010.

<span class="mw-page-title-main">Transdermal analgesic patch</span> Medicated adhesive patch

A transdermal analgesic or pain relief patch is a medicated adhesive patch used to relieve minor to severe pain. There are many types of analgesic patches based on the main ingredients in the patches. These include patches containing counterirritants, which are used to treat mild to moderate pain, and patches containing opioids such as buprenorphine and fentanyl, used to relieve moderate to severe pain. Fentanyl is often used for opioid-tolerant patients. Nitroglycerin, also known as glyceryl trinitrate (GTN), a medication used for heart failure, high blood pressure, anal fissures, painful periods, and to treat and prevent chest pain, can also be found in patches. Beyond these are patches that contain drugs such as diclofenac and lidocaine and various other drugs. The main purpose of transdermal analgesic patches are to administer drugs in a more viable way to patients, as opposed to oral consumption or intravenous administration such as an injection.

<span class="mw-page-title-main">Ray L. Watts</span>

Ray Lannom Watts is an American physician-researcher in neurology, educator and university administrator. Watts has served as the seventh president of the University of Alabama at Birmingham (UAB) since February 2013 and is the longest-serving president in UAB history.

<span class="mw-page-title-main">Disappearing polymorph</span> Phenomenon in materials science

In materials science, a disappearing polymorph is a form of a crystal structure that is suddenly unable to be produced, instead transforming into a different crystal structure with the same chemical composition during nucleation. Sometimes the resulting transformation is extremely hard or impractical to reverse, because the new polymorph may be more stable. It is hypothesized that contact with a single microscopic seed crystal of the new polymorph can be enough to start a chain reaction causing the transformation of a much larger mass of material. Widespread contamination with such microscopic seed crystals may lead to the impression that the original polymorph has "disappeared". In a few cases such as progesterone and paroxetine hydrochloride, the disappearance is global, and it is suspected that it is because earth's atmosphere is permeated with tiny seed crystals. It is believed that seeds as small as a few million molecules is sufficient for converting one morph to another, making unwanted disappearance of morphs particularly difficult to prevent.

References

  1. VCU Department of Chemistry recognizing Dr. Minaskanian as a research professor and faculty (VCU Department of Chemistry Archived 2013-12-10 at the Wayback Machine )
  2. Document excerpt filed by Aderis Pharmaceuticals INC. filling Dr. Gevork Minaskanian as the Vice President of Synthetic Chemistry at Aderis (excerpt from a S-1/A SEC Filin)
  3. VCU Department of Chemistry recognizing Dr. Minaskanian research work on rotigotine and Neupro as an unprecedented medication for the benefit of millions of Parkinson’s patients worldwide (VCU Department of Chemistry)
  4. US Patent 5,470,848 Dr. Minaskanian's latest patents related to the subject of transdermal delivery systems from 1995 (US Patent 5,470,848)
  5. Dr. Minaskanian's older US patents related to the subject of transdermal delivery systems from 1989 (US Patent 4,801,586)
  6. Another US Patent that Dr. Minaskanian has related to Neupro (US Patent 5,234,959)
  7. Another US Patent that Dr. Minaskanian has related to Neupro (US Patent 5,118,676)
  8. US Patent 7,309,497 containing a list of some of Dr. Minaskanian's work used by Schwarz Pharma AG to do newer research (US Patent 7,309,497 7)